首页> 中文期刊> 《中国药业》 >美沙拉嗪联合双歧三联活菌治疗重度溃疡性结肠炎的疗效评价

美沙拉嗪联合双歧三联活菌治疗重度溃疡性结肠炎的疗效评价

         

摘要

目的 探讨美沙拉嗪联合双歧三联活菌治疗重度溃疡性结肠炎的临床效果.方法 将重度溃疡性结肠炎患者120例随机分为两组,观察组采用美沙拉嗪联合双歧三联活菌给药方案,对照组只给予美沙拉嗪.结果 观察组治愈率和总有效率均明显高于对照组(P<0.05);两组血清中的C反应蛋白含量均明显降低,观察组含量明显较对照组小(P<0.05).结论 美沙拉嗪联合双歧三联活菌治疗重度溃疡性结肠炎的临床效果显著.%Objective To discuss the clinical effect of mesalazine combined with tri-bifidobacteria in the treatment of severe ulcerative colitis.Methods 120 cases of severe ulcerative colitis patients from in our hospital were randomly divided into two groups.The observation group took the treatment regimen of mesalazine combined with tri-bifidobacteria,while the control group was given only mesalazine.Results The cure rate and the total effective rate in the observation group were significantly higher than those in the control group,the differences between the two groups showing statistical significance (P < 0.05).The effective rate in the observation group of 94.8% was significantly higher than the control group of 90.3%.The serum C-reactive protein levels in patients had a significantly decreasing.The serum level of C-reactive protein after treatment in the observation group was significantly decreased compared with the control group,indicating that the improving situation of inflammation in the observation group was significantly better than that in the control group with statistical difference between the two groups (P < 0.05).Conclusion Mesalazine combined with tri-bifidobacteria is significantly effective in the treatment of severe ulcerative colitis.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号